CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

<h4>Background</h4>The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are important second messengers and are potential biomarkers for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Patrick Oeckl, Petra Steinacker, Stefan Lehnert, Sarah Jesse, Hans A Kretzschmar, Albert C Ludolph, Markus Otto, Boris Ferger
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/3ca108ae1354458b855b29fa89919062
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3ca108ae1354458b855b29fa89919062
record_format dspace
spelling oai:doaj.org-article:3ca108ae1354458b855b29fa899190622021-11-18T07:26:13ZCSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.1932-620310.1371/journal.pone.0032664https://doaj.org/article/3ca108ae1354458b855b29fa899190622012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22396786/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are important second messengers and are potential biomarkers for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Creutzfeldt-Jakob disease (CJD).<h4>Methodology/principal findings</h4>Here, we investigated by liquid chromatography/tandem mass spectrometry (LC-MS/MS) the cerebrospinal fluid (CSF) concentrations of cAMP and cGMP of 82 patients and evaluated their diagnostic potency as biomarkers. For comparison with a well-accepted biomarker, we measured tau concentrations in CSF of CJD and control patients. CJD patients (n = 15) had lower cAMP (-70%) and cGMP (-55%) concentrations in CSF compared with controls (n = 11). There was no difference in PD, PD dementia (PDD) and ALS cases. Receiver operating characteristic (ROC) curve analyses confirmed cAMP and cGMP as valuable diagnostic markers for CJD indicated by the area under the curve (AUC) of 0.86 (cAMP) and 0.85 (cGMP). We calculated a sensitivity of 100% and specificity of 64% for cAMP and a sensitivity of 67% and specificity of 100% for cGMP. The combination of both nucleotides increased the sensitivity to 80% and specificity to 91% for the term cAMPxcGMP (AUC 0.92) and to 93% and 100% for the ratio tau/cAMP (AUC 0.99).<h4>Conclusions/significance</h4>We conclude that the CSF determination of cAMP and cGMP may easily be included in the diagnosis of CJD and could be helpful in monitoring disease progression as well as in therapy control.Patrick OecklPetra SteinackerStefan LehnertSarah JesseHans A KretzschmarAlbert C LudolphMarkus OttoBoris FergerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 3, p e32664 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Patrick Oeckl
Petra Steinacker
Stefan Lehnert
Sarah Jesse
Hans A Kretzschmar
Albert C Ludolph
Markus Otto
Boris Ferger
CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
description <h4>Background</h4>The cyclic nucleotides cyclic adenosine-3',5'-monophosphate (cAMP) and cyclic guanosine-3',5'-monophosphate (cGMP) are important second messengers and are potential biomarkers for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and Creutzfeldt-Jakob disease (CJD).<h4>Methodology/principal findings</h4>Here, we investigated by liquid chromatography/tandem mass spectrometry (LC-MS/MS) the cerebrospinal fluid (CSF) concentrations of cAMP and cGMP of 82 patients and evaluated their diagnostic potency as biomarkers. For comparison with a well-accepted biomarker, we measured tau concentrations in CSF of CJD and control patients. CJD patients (n = 15) had lower cAMP (-70%) and cGMP (-55%) concentrations in CSF compared with controls (n = 11). There was no difference in PD, PD dementia (PDD) and ALS cases. Receiver operating characteristic (ROC) curve analyses confirmed cAMP and cGMP as valuable diagnostic markers for CJD indicated by the area under the curve (AUC) of 0.86 (cAMP) and 0.85 (cGMP). We calculated a sensitivity of 100% and specificity of 64% for cAMP and a sensitivity of 67% and specificity of 100% for cGMP. The combination of both nucleotides increased the sensitivity to 80% and specificity to 91% for the term cAMPxcGMP (AUC 0.92) and to 93% and 100% for the ratio tau/cAMP (AUC 0.99).<h4>Conclusions/significance</h4>We conclude that the CSF determination of cAMP and cGMP may easily be included in the diagnosis of CJD and could be helpful in monitoring disease progression as well as in therapy control.
format article
author Patrick Oeckl
Petra Steinacker
Stefan Lehnert
Sarah Jesse
Hans A Kretzschmar
Albert C Ludolph
Markus Otto
Boris Ferger
author_facet Patrick Oeckl
Petra Steinacker
Stefan Lehnert
Sarah Jesse
Hans A Kretzschmar
Albert C Ludolph
Markus Otto
Boris Ferger
author_sort Patrick Oeckl
title CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
title_short CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
title_full CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
title_fullStr CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
title_full_unstemmed CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.
title_sort csf concentrations of camp and cgmp are lower in patients with creutzfeldt-jakob disease but not parkinson's disease and amyotrophic lateral sclerosis.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/3ca108ae1354458b855b29fa89919062
work_keys_str_mv AT patrickoeckl csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT petrasteinacker csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT stefanlehnert csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT sarahjesse csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT hansakretzschmar csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT albertcludolph csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT markusotto csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
AT borisferger csfconcentrationsofcampandcgmparelowerinpatientswithcreutzfeldtjakobdiseasebutnotparkinsonsdiseaseandamyotrophiclateralsclerosis
_version_ 1718423467398791168